Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
AOD 9604 Studies on Obesity Models In obese murine models, both growth hormone and AOD 9604 have been linked to reductions in body fat mass, though the outcomes appeared different in lean models
Typical injectable GHK-Cu dose ranges Standard starting dose: 1 mg per day subcutaneous Conservative / beginner dose: 0.5 mg per day Intensive / wound-healing dose: 23 mg per day Upper research range: 4 mg per day (rarely exceeded) Frequency: once daily, or split into morning + evening microdoses for steadier levels Route: subcutaneous (SC) injection - typically abdomen , thigh or flank
A separate Phase 1/2 study sponsored by Hudson Biotech (NCT07487363) is the first publicly registered US trial using the LKKTETQ 7-mer by name, in stable atherosclerotic cardiovascular disease with cardiovascular-biomarker endpoints (recruiting as of May 2026)
The crew still shows up
It also helps to know the wider risk
